FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3105808417> ?p ?o ?g. }

• W3105808417 endingPage "149" @default.
• W3105808417 startingPage "149" @default.
• W3105808417 abstract "There is an urgent need for inexpensive and minimally invasive blood biomarkers for Alzheimer disease (AD) that could be used to detect early disease changes.To assess how early in the course of AD plasma levels of tau phosphorylated at threonine 217 (P-tau217) start to change compared with levels of established cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers of AD pathology.This cohort study included cognitively healthy control individuals (n = 225) and participants with subjective cognitive decline (n = 89) or mild cognitive impairment (n = 176) from the BioFINDER-2 study. Participants were enrolled at 2 different hospitals in Sweden from January 2017 to October 2019. All study participants underwent plasma P-tau217 assessments and tau- and amyloid-β (Aβ)-PET imaging. A subcohort of 111 participants had 2 or 3 tau-PET scans.Changes in plasma P-tau217 levels in preclinical and prodromal AD compared with changes in CSF P-tau217 and PET measures.Of 490 participants, 251 were women (51.2%) and the mean (SD) age was 65.9 (13.1) years. Plasma P-tau217 levels were increased in cognitively unimpaired participants with abnormal Aβ-PET but normal tau-PET in the entorhinal cortex (Aβ-PET+/ tau-PET- group vs Aβ-PET-/ tau-PET- group: median, 2.2 pg/mL [interquartile range (IQR), 1.5-2.9 pg/mL] vs 0.7 pg/mL [IQR, 0.3-1.4 pg/mL]). Most cognitively unimpaired participants who were discordant for plasma P-tau217 and tau-PET were positive for plasma P-tau217 and negative for tau-PET (P-tau217+/tau-PET-: 36 [94.7%]; P-tau217-/tau-PET+: 2 [5.3%]). Event-based modeling of cross-sectional data predicted that in cognitively unimpaired participants and in those with mild cognitive impairment, both plasma and CSF P-tau217 would change before the tau-PET signal in the entorhinal cortex, followed by more widespread cortical tau-PET changes. When testing the association with global Aβ load in nonlinear spline models, both plasma and CSF P-tau217 were increased at lower Aβ-PET values compared with tau-PET measures. Among participants with normal baseline tau-PET, the rates of longitudinal increase in tau-PET in the entorhinal cortex were higher in those with abnormal plasma P-tau217 at baseline (median standardized uptake value ratio, 0.029 [IQR, -0.006 to 0.041] vs -0.001 [IQR, -0.021 to 0.020]; Mann-Whitney U, P = .02).In this cohort study, plasma P-tau217 levels were increased during the early preclinical stages of AD when insoluble tau aggregates were not yet detectable by tau-PET. Plasma P-tau217 may hold promise as a biomarker for early AD brain pathology." @default.
• W3105808417 created "2020-11-23" @default.
• W3105808417 creator A5001021000 @default.
• W3105808417 creator A5023509155 @default.
• W3105808417 creator A5023889784 @default.
• W3105808417 creator A5024645775 @default.
• W3105808417 creator A5031901743 @default.
• W3105808417 creator A5035346809 @default.
• W3105808417 creator A5043568262 @default.
• W3105808417 creator A5043911303 @default.
• W3105808417 creator A5049277633 @default.
• W3105808417 creator A5083219599 @default.
• W3105808417 date "2021-02-01" @default.
• W3105808417 modified "2023-10-01" @default.
• W3105808417 title "Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease" @default.
• W3105808417 cites W1972025839 @default.
• W3105808417 cites W1974300727 @default.
• W3105808417 cites W2052742260 @default.
• W3105808417 cites W2096890121 @default.
• W3105808417 cites W2120402847 @default.
• W3105808417 cites W2136195493 @default.
• W3105808417 cites W2737811824 @default.
• W3105808417 cites W2750075274 @default.
• W3105808417 cites W2763470121 @default.
• W3105808417 cites W2784445653 @default.
• W3105808417 cites W2795642715 @default.
• W3105808417 cites W2798054687 @default.
• W3105808417 cites W2892024211 @default.
• W3105808417 cites W2910556588 @default.
• W3105808417 cites W2952677120 @default.
• W3105808417 cites W2962893048 @default.
• W3105808417 cites W2989446795 @default.
• W3105808417 cites W3002183655 @default.
• W3105808417 cites W3009441391 @default.
• W3105808417 cites W3009833354 @default.
• W3105808417 cites W3011927235 @default.
• W3105808417 cites W3014779409 @default.
• W3105808417 cites W3016877536 @default.
• W3105808417 cites W3021135759 @default.
• W3105808417 cites W3045997188 @default.
• W3105808417 cites W4211213171 @default.
• W3105808417 doi "https://doi.org/10.1001/jamaneurol.2020.4201" @default.
• W3105808417 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7653537" @default.
• W3105808417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33165506" @default.
• W3105808417 hasPublicationYear "2021" @default.
• W3105808417 type Work @default.
• W3105808417 sameAs 3105808417 @default.
• W3105808417 citedByCount "145" @default.
• W3105808417 countsByYear W31058084172012 @default.
• W3105808417 countsByYear W31058084172021 @default.
• W3105808417 countsByYear W31058084172022 @default.
• W3105808417 countsByYear W31058084172023 @default.
• W3105808417 crossrefType "journal-article" @default.
• W3105808417 hasAuthorship W3105808417A5001021000 @default.
• W3105808417 hasAuthorship W3105808417A5023509155 @default.
• W3105808417 hasAuthorship W3105808417A5023889784 @default.
• W3105808417 hasAuthorship W3105808417A5024645775 @default.
• W3105808417 hasAuthorship W3105808417A5031901743 @default.
• W3105808417 hasAuthorship W3105808417A5035346809 @default.
• W3105808417 hasAuthorship W3105808417A5043568262 @default.
• W3105808417 hasAuthorship W3105808417A5043911303 @default.
• W3105808417 hasAuthorship W3105808417A5049277633 @default.
• W3105808417 hasAuthorship W3105808417A5083219599 @default.
• W3105808417 hasBestOaLocation W31058084171 @default.
• W3105808417 hasConcept C119060515 @default.
• W3105808417 hasConcept C126322002 @default.
• W3105808417 hasConcept C142724271 @default.
• W3105808417 hasConcept C15744967 @default.
• W3105808417 hasConcept C199374082 @default.
• W3105808417 hasConcept C2775842073 @default.
• W3105808417 hasConcept C2779134260 @default.
• W3105808417 hasConcept C2779483572 @default.
• W3105808417 hasConcept C2779651940 @default.
• W3105808417 hasConcept C2780715579 @default.
• W3105808417 hasConcept C2781161787 @default.
• W3105808417 hasConcept C2989005 @default.
• W3105808417 hasConcept C71924100 @default.
• W3105808417 hasConcept C72563966 @default.
• W3105808417 hasConceptScore W3105808417C119060515 @default.
• W3105808417 hasConceptScore W3105808417C126322002 @default.
• W3105808417 hasConceptScore W3105808417C142724271 @default.
• W3105808417 hasConceptScore W3105808417C15744967 @default.
• W3105808417 hasConceptScore W3105808417C199374082 @default.
• W3105808417 hasConceptScore W3105808417C2775842073 @default.
• W3105808417 hasConceptScore W3105808417C2779134260 @default.
• W3105808417 hasConceptScore W3105808417C2779483572 @default.
• W3105808417 hasConceptScore W3105808417C2779651940 @default.
• W3105808417 hasConceptScore W3105808417C2780715579 @default.
• W3105808417 hasConceptScore W3105808417C2781161787 @default.
• W3105808417 hasConceptScore W3105808417C2989005 @default.
• W3105808417 hasConceptScore W3105808417C71924100 @default.
• W3105808417 hasConceptScore W3105808417C72563966 @default.
• W3105808417 hasIssue "2" @default.
• W3105808417 hasLocation W31058084171 @default.
• W3105808417 hasLocation W31058084172 @default.
• W3105808417 hasLocation W31058084173 @default.
• W3105808417 hasOpenAccess W3105808417 @default.
• W3105808417 hasPrimaryLocation W31058084171 @default.

• next